SMi are delighted to present our 9th annual Asthma & COPD event to be held in Central London on Monday 15th & Tuesday 16th of April 2013. Following on from the great success of our previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, Asthma & COPD 2013 will continue to bring forward leading industry experts and esteemed academic KOLs in the field to discuss the latest developments and challenges alongside strategies to improve asthma and COPD patient outcomes.
An estimated 65 million people currently suffer from COPD globally with 300 million asthma sufferers. Considering that patients with COPD are often misdiagnosed with asthma due to the understated yet significant similarities between the two conditions, it is increasingly important to support respiratory research in order to phenotype patients for personalized medicine and reduce associated costs for research.
With the global markets for asthma & COPD drugs to hit $47 billion in 2017, Asthma & COPD 2013 will present a uniquely informative platform for those new to the field and for established respiratory professionals alike. This event will also present an ideal opportunity to network with key industry professionals and absorb knowledge from leaders in the fields of asthma and COPD.
• Compare and contrast exacerbations of Asthma & COPD
• Explore current and novel inhalation devices alongside combination therapies
• Establish patient phenotyping, by way of biomarkers for Asthma & COPD, for efficient and effective therapeutic outcomes
• Investigate patient reported outcomes (PROs)
• Highlight current and novel treatments such as CCR3 antagonists and cytokine modulators/inhibitors
• Determine the unmet needs in Asthma & COPD and discuss how these needs can be addressed
• Network with key industry professionals and KOLs in Asthma & COPD
Professor Peter Barnes, Head of Respiratory Medicine at Imperial College London commented “ I am happy to be involved in this important meeting that provides an update on new treatments for COPD and asthma as this is a key therapeutic area, where several new approaches are in development”
This event is unmissable for Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in
- Respiratory Medicine
- Respiratory Pharmacology
- Inflammatory Disease
- Research Immunology
- Pharmacology
- Respiratory Licensing
- Respiratory, Inflammation and Autoimmunity
- Pulmonary Disease
- Immunology
- Respiratory Cell Biology
- Respiratory Therapeutics
- Inhalation Devices
- Medical Devices
- Inflammation Discovery
- Respiratory Medicine Regulation
|
|
Attendees at previous SMi Asthma & COPD events include: 3M Healthcare, 4SC, Accovion, Actelion, Actimis, Activaero, Aeropharm, AstraZeneca, Bayer, Bedfont Scientific, Biomedical Systems Europe, Biotie Therapies, Boehringer Ingelheim, CareFusion, Centocor, Chiesi, Deepbreeze, Galapagos, Genentech, GSK, Grunenthal, Laboratorios Almirall, MedImmune, Merck, Mpex, Munidpharma, Napp, Novartis, Nycomed, Pfizer,Revotar, Roche, Sanofi-Aventis, Schering Plough, Sepracor, Synairgen, Topigen, UCB, Vitalograph
AlgiPharma AS; Almirall; Asthma Uk; Astrazeneca; AstraZeneca GmbH; Barts & The London NHS Trust; Biomedical Systems Europe; Biopharm Insight; Boehringer Ingelheim; Boehringer-Ingelheim Pharma; Celbo AB; Chiesi Farmaceutici S. P. A. ; Decision Resources; ElectroCore Medical, AB; European Medicines Agency (E M E A); Forest Research Institute; Geoff Tovey Associates; GlaxoSmithKline; Glenmark Pharmaceutials; Grunenthal; GSK; Helsinki University Central Hospital; Imperial College; Imperial School Of Medicine London; MedPartners; N A P P Pharmaceutical; National Heart and Lung Institute Imperial College; National Heart and Lung Institute Imperial College London; nSpire Health Ltd; Oxagen Ltd; Prosonix Ltd; Pulmagen Therapeutics; Revotar Biopharmaceuticals; Teva UK Limited; Teva UK Ltd; UCB-Celltech; University College London; University of Groningen University Medical Centre Groningen Centre for Medical Biomics; Vectura; Vitalograph;